The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family

Patricia Boya, Maria Celia Morales, Rosa Ana Gonzalez-Polo, Karine Andreau, Isabelle Gourdier, Jean Luc Perfettini, Nathanael Larochette, Aurélien Deniaud, Fanny Baran-Marszak, Remy Fagard, Jean Feuillard, Aintzane Asumendi, Martine Raphael, Bernard Pau, Catherine Brenner, Guido Kroemer

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    84 Citations (Scopus)

    Résumé

    N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a potent chemopreventive agent whose effect has been suggested to involve apoptosis induction. 4-HPR induces a loss of the mitochondrial transmembrane potential and the mitochondrial release of cytochrome c before caspase activation. Inhibition of mitochondrial membrane permeabilization (MMP) by transfection with Bcl-2 or the Cytomegalovirus UL37 gene product vMIA prevented caspase activation and cell death. In contrast to other retinoid derivatives, 4-HPR has no direct MMP-inducing effects when added to isolated mitochondria or when added to proteoliposomes containing the MMP-regulatory permeability transition pore complex (PTPC). Moreover, although reactive oxygen species (ROS) over-production appears to be instrumental for 4-HPR-induced MMP and apoptosis, inhibition of the NF-κB or p53-mediated signal transduction pathways failed to modulate 4-HPR-induced apoptosis. 4-HPR was found to cause an antioxidant-inhibitable conformational change of both Bax and Bak, leading to the exposure of their N-termini and to the mitochondrial relocalization of Bax. Cells with a Bax-/- Bak-/- genotype were resistant against the 4-HPR-induced MMP, overproduction of ROS and cell death. Altogether, these data indicate that 4-HPR induces MMP through an ROS-mediated pathway that involves the obligatory contribution of the proapopotic Bcl-2 family members Bax and/or Bak.

    langue originaleAnglais
    Pages (de - à)6220-6230
    Nombre de pages11
    journalOncogene
    Volume22
    Numéro de publication40
    Les DOIs
    étatPublié - 18 sept. 2003

    Contient cette citation